Jiangsu Bioperfectus Technologies Co

Jiangsu Bioperfectus Technologies Co Gross Margin

The Gross Margin of Jiangsu Bioperfectus Technologies Co (688399.SS) as of Nov 4, 2026 is 100.00 %. In the previous year, Gross Margin was 57.77 % — a change of 73.10% (higher).

Gross Margin

100.00 %

YoY

73.10%

Last updated:

Gross Margin of Jiangsu Bioperfectus Technologies Co is 2025 100.00 % . Gross Margin of Jiangsu Bioperfectus Technologies Co was 2024 57.77 % . It decreases by 73.10% higher compared to the previous year.

For Jiangsu Bioperfectus Technologies Co, the gross margin of 102.6% is up versus 69.1% a few years ago.

The Jiangsu Bioperfectus Technologies Co Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
81.81 CNY
Jan 1, 2019
81.75 CNY
Jan 1, 2020
77.54 CNY
Jan 1, 2021
69.00 CNY
Jan 1, 2022
57.00 CNY
Jan 1, 2023
37.02 CNY
Jan 1, 2024
57.77 CNY
Jan 1, 2025
100.00 CNY
The Jiangsu Bioperfectus Technologies Co Gross Margin history
YEARGross MarginYoY
100.00 %+73.10%
57.77 %+56.07%
37.02 %-35.05%
57.00 %-17.40%
69.00 %-11.01%
77.54 %-5.15%
81.75 %-0.07%
81.81 %-0.92%
82.57 %+1.26%
81.55 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Jiangsu Bioperfectus Technologies Co Stock analysis

What does Jiangsu Bioperfectus Technologies Co do? Jiangsu Bioperfectus Technologies Co., Ltd. generates revenue through the research, development, production, and sale of in vitro diagnostic reagents and supporting testing instruments. The company's primary products include in vitro diagnostic reagents, supporting testing instruments, and in vitro testing services, which are utilized in infectious disease prevention and control, clinical testing, large-scale population screening, and prenatal and postnatal care management. Domestic and overseas markets represent the main sales channels for these products, with the firm targeting healthcare providers and laboratories that require diagnostic solutions for disease detection and patient care. The company's focus on in vitro diagnostic reagents and supporting instruments positions it within the healthcare sector, serving customers who need reliable testing tools for clinical and public health applications. By offering comprehensive diagnostic solutions, Jiangsu Bioperfectus addresses the needs of medical institutions and public health initiatives, particularly in areas such as infectious disease management and maternal care. The firm's product portfolio supports both routine clinical testing and specialized population screening programs. Jiangsu Bioperfectus Technologies Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jiangsu Bioperfectus Technologies Co stock

Gross Margin of Jiangsu Bioperfectus Technologies Co is 100.00 % in 2025.

Gross Margin of Jiangsu Bioperfectus Technologies Co changed from 57.77 % to 100.00 %, representing a 73.10% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Jiangsu Bioperfectus Technologies Co since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Jiangsu Bioperfectus Technologies Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Jiangsu Bioperfectus Technologies Co

All Key Metrics — Jiangsu Bioperfectus Technologies Co